The bursa of Fabricius (BF), which is unique to birds, serves as the central humoral immune organ and plays a significant role in B lymphocyte differentiation. In this study, a new bursal peptide (BP-IV) was isolated from BF, which promoted colony-forming unit pre-B formation and regulated B cell differentiation. BP-IV also exerted immunomodulatory effects on antigen-specific immune responses via both humoral and cellular immunity in chicken and mice that had been immunized with inactivated avian influenza virus (AIV; H9N2 subtype), including enhancing AIV-specific antibody and cytokine production. The results of this study provided novel insights into the use of a potential candidate reagent for B cell development and future immuno-pharmacological use.
Introduction
The bursa of Fabricius (BF), which serves as the primary humoral immune organ and is unique to birds [5] , is critical to early B-lymphocyte proliferation and differentiation [4, 8, 14] . The process of B-cell maturation was elucidated in birds. Thus, the "B" refers to the BF. However, similar to the T-cell-differentiating thymus, the B-cell-differentiating organ has not yet been identified in mammals [3] . As a result, the BF serves as a unique model for studying basic immunology.
Avian species are unique in that they possess the primary lymphoid organ, BF, which is required for the differentiation of B cells [10] . Specifically, the differentiation and development of avian B cells in the BF is the primary contributor to production of B cells and provides key insights into their expansion. During myeloid differentiation, transcription factor PU.1 is required for formation of the earliest myeloid and lymphoid progenitor cells [9] . The ablation of PU.1 in mice leads to the complete absence of B cells and macrophages, suggesting that expression of the PU.1 gene is tightly controlled during hematopoietic differentiation [15, 19] . However, the molecular mechanisms leading to appropriated PU.1 levels are not fully understood.
Several biologically active factors have been reported to be contained in the BF. Specifically, high doses of chicken BF extract have been used to induce blastogenic responses to T-cell mitogens [17] . As a specific factor, bursin is responsible for B-cell differentiation [11] . Specifically, it selectively stimulates the differentiation of avian B cells, rather than that of T cells, from their precursors in vitro [1, 3] , and promotes immunoglobulin (Ig) switching from IgM to IgG [2] . Bursal anti-steroidogenic peptide is responsible for synchronizing B-cell division during embryogenesis and the neonatal period [16] . Bursopentin (BP5) has been shown to induce B-lymphocyte proliferation via various signaling pathways [12] . Additionally, bursal peptide (BP) 11 was found to regulate B-cell development and antigen-specific immune responses [13] . Although the molecular basis and mechanisms of action of the aforementioned peptides from BF have been well characterized, there should be additional BF peptides regulating B-cell development and immune response. A new bursal peptide (BP-IV) was isolated from BF using reversed-phase high-performance liquid chromatography (RP-HPLC) and matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF-MS), presenting different biological effects such as promotion of colony-forming unit (CFU) pre-B formation and B cell differentiation and exertion of immunomodulatory function on antigen-specific immune responses in chickens and mice.
Materials and Methods

Animals
C56BL/6 mice and BALB/c (4-6 weeks old, 18-21 g) were obtained from Yang Zhou University (Yangzhou, China). The 21-day old fertilized eggs of White Leghorn chickens (LSL) were purchased from Qinglongshan farm. The guidelines of the Animal Care and Ethics Committee of Nanjing Agricultural University (approval no. 200709005) were followed for all animal experiments.
Isolation and identification of peptides from BF
The bursa of 1,000 fertilized eggs of White Leghorn chickens were collected, after which the peptides were purified from the bursa by RP-HPLC, as previous described [13, 21] . The elutions were collected and the novel peptides were analyzed using MALDI-TOF-MS (FLEX series; Bruker, Germany). Bursal peptide (KNEVEEEAKTP) and scrambled peptide (VEPAEEKTENK) were synthesized by Shanghai Taishi Bioscience (China).
CFU pre-B assay
The CFU pre-B assay was performed as previously described [7] . Briefly, bone marrow (BM) cells (1 × 10 6 cells/mL) from C56BL/6 mice were suspended in Iscove's Modified Dulbecco's Medium containing 1% methylcellulose, 2 mM L-glutamine, 10% fetal calf sera, 50 M 2-mercaptoethanol, 0.1 g/L streptomycin, 105 U/mL penicillin, and interleukin (IL)-7 (10 ng/mL). The BM cells were then treated with the IL-7 (10 ng/mL) and BP-IV or BP-IV-scrambled, mixed with methylcellulose (both added immediately before plating), and plated in 35 mm culture dishes, then incubated at 37 o C under 5% CO 2 for 7 days. The CFU pre-B formation was then determined. Colonies consisting of at least 100 cells were determined as CFU pre-B formation.
Flow cytometry
BM cells (1 × 10 6 ) from C56BL/6 mice were maintained with BP-IV or BP-IV-scrambled (25 g/mL) in the presence of IL-7 (10 ng/mL) for 7 days. The cells were then stained with phycoerythrin (PE)-Cy5 anti-B220 (RA3-6B2), PE-CD43 (eBioR2/60) and PE-Cy7 anti-IgM (II/41) purchased from eBioscience (USA). B-cell progenitors were defined by the presence of the following antibody combinations: pro-B cells (B220 ). Samples were analyzed using the Cytomics FC500 MPL flow cytometry system (Beckman Coulter, USA) and Cytomics FC500 Flow Cytometry CXP software. A total of 10,000 cells were analyzed for each sample. The cells were also sorted using a MoFlo XDP cell sorter and the Summit 4.1 software to ＞ 98% purity.
Real-time polymerase chain reaction (RT-PCR)
Total RNA of isolated pro-B cells, pre-B cells and immature/mature (iMB/MB) cells were isolated using TRIzol reagent (Invitrogen, USA). DNA-free total RNA (100 ng) was then subjected to cDNA synthesis using the PrimeScript RT reagent Kit (Takara Bio, Japan) according to the manufacturer's instructions. Additionally, RT-PCR was performed using a SYBR Premix Ex Taq (Perfect Real Time) kit (Takara Bio) in accordance with the manufacturer's protocols. The following primers were used: PU.1 (forward, 5´-GCATCTGGTGG GTGGACAA-3´; reverse, 5´-TCTTGCCGTAGTTGCGCAG-3´); glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (forward, 5´-GTCAACGGATTTGGTCGTATT-3´; reverse, 5´-GATCTCGCTCCTGGAAGATGG-3´) [13] .
Animal experiment
Sixty 21 day-old chickens that had been immunized with AIV vaccine (AIV, H9N2 subtype) (10 7 TCID 50 /0.1 mL) were used to evaluate the immunomodulatory functions of the BP-IV. Chickens (10 chickens per group) were divided to six groups and immunized subcutaneously on day 1, then boosted on day 14 with AIV vaccine at 0.5 mL per dose (10 7 TCID 50 /0.1 mL) along with or without BP-IV (0.2, 1 and 5 mg/kg). Control animals were subsequently immunized with AIV vaccine or BP-IV-scrambled (1 mg/kg). At day 7 after the second immunization, the sera of immunized chickens were collected and the cytokines of IL-4 and IFN- were measured using commercial avian cytokine ELISA kits (R&D Systems, USA). At 2 weeks after the first and second immunizations, the sera of immunized chickens were collected. Samples were tested for hemagglutination-inhibition (HI) antibody as previously described, and the immunized peripheral lymphocyte proliferation was measured by standard MTT assay [13] .
Forty BALB/c female mice (6-8 weeks old) were used to evaluate the immunomodulatory roles of the BP-IV. Mice were intraperitoneally immunized with a 0.2 mL AIV vaccine (10 7 TCID 50 /0.1 mL) containing 1 mg/kg BP-IV or BP-IV-scrambled on days 0 and 14, respectively, and the sera were collected at 2 weeks after the first and second immunization. The antigen specific antibody responses (IgG) were tested using the enzyme-linked immunosorbent assay (ELISA) method as previously described [13] . At day 7 after the final immunization, mice cytokine ELISA kits (R&D Systems) were used to detect the cytokine levels of IL-4 and IFN- according to the manufacturer's instructions. The spleen cells were then isolated from immunized mice. Red blood cells were lysed using ammonium chloride solution, and the remaining cells were stained with the specific mAbs CD3, CD4, and CD8 for immunophenotyping of spleen T lymphocytes, which was conducted using a BD FACS Calibur flow cytometer (BD Biosciences, USA). A total of 10,000 cells were analyzed for each sample.
Statistical analysis
Results were expressed as the means ± SD. Duncan's multiple range test was used to identify differences among groups. Analyses were conducted with the SPSS 16.0 software (SPSS, USA), p value ＜ 0.05 was considered to be statistically significant.
Results
Isolation and characterization of novel peptide BP-IV
The supernatant of avian BF extract was purified by RP-HPLC, then analyzed by MALDI-TOF-MS. BP-IV was eluted in the arrow-marked peak (panel A in Fig. 1 ). The molecular weight of this bursal sample was 1273.34 (m/z), and the amino acid sequence was KNEVEEEAKTP. This sequence has not been reported previously, and was designated as BP-IV (panel B in Fig. 1 ). The amino acid sequence of BP-IV was aligned with the National Center for Biotechnology Information Non-redundant and Expressed Sequence Tags databases. The results showed that BP-IV was homologous to various proteins in Gallus gallus, including calcipressin-1, which is essential to the immune system and T cell activation. BP-IV was also homologous to various human and mouse proteins, such as NEFH protein (human) and BCL2-like 13 (mouse).
BP-IV promotes CFU pre-B formation and modulates B-cell development
CFU pre-B formation assays were used to investigate the roles of BP-IV in B-cell progenitor development. We found that BP-IV promoted CFU-pre-B formation in a dose-dependent manner at concentrations ranging from 1 to 25 g/mL (1 g/mL, p ＜ 0.05; 5 g/mL, p ＜ 0.05; 25 g/mL, p ＜ 0.05) when compared to the control and BP-IV-scrambled, suggesting that BP-IV has the potential to promote the formation of CFU pre-B (panel A in Fig. 2) . Furthermore, BM cells isolated from C56BL/6 mice were cultured in the presence of IL-7 (10 ng/mL) with BP-IV (25 g/mL) for 7 days, after which B-cell differentiation was assessed by flow cytometric analysis. The percentages of iMB/MB cells in the cultures were increased by BP-IV treatment (p ＜ 0.05), and the percentages of pro-B cells were decreased by BP-IV treatment (p ＜ 0.05) (panel B in Fig. 2) .
To investigate the functional role of BP-IV on B cell development, RT-PCR was employed to analyze the gene expression of BM cells after BP-IV treatment. Given that B-cell progenitors continue to mature when cultured in vitro, we investigated the effects of BP-IV exposure on B-cell progenitor gene expression. BM cell cultures were treated with BP-IV for 24 h, then sorted into pro-B, pre-B, and iMB/MB cell populations (panel C in Fig. 2) . We observed significant differences in gene expression between progenitor populations treated with BP-IV or BP-IV-scrambled prior to sorting. Among major hematopoietic regulators, we found that PU.1 gene expression was significantly suppressed by BP-IV treatment in the pro-B, pre-B and iMB/MB cell populations (panel D in Fig. 2) . The current study demonstrated that BP-IV can inhibit the transcriptional activation of PU.1, which may partly explain the mechanism by which BP-IV promotes IL-7-induced B-cell development.
Immunomodulatory characteristics of BP-IV on chicken as the host animal model experiment
Since BP-IV was obtained from chicken bursa of Fabricius, it led us to examine the effects of BP-IV on immune responses. Chickens were injected with BP-IV and AIV vaccine and the levels of antibodies were measured (panels A-C in Fig. 3) . Antibodies from chicken immunized with BP-IV and AIV vaccine increased significantly (p ＜ 0.05), with the levels of antibodies from chickens immunized with AIV vaccine and BP-IV (5 mg/kg) being highest among the three concentrations (panel A in Fig. 3 ). These results suggested that BP-IV promotes AIV-specific immunoglobulin secretion in vivo.
To determine if BP-IV enhances a specific cytokines response, IL-4 and IFN- cytokines were measured by the ELISA method. When compared to the control (chickens that received AIV vaccine), IL-4 and IFN-production increased significantly in response to the two immunizations with BP-IV (IL-4: 0.2, 1, and 5 mg/kg, p ＜ 0.01; IFN-: 0.2, 1, and 5 mg/kg, p ＜ 0.01) (panel B in Fig. 3) .
Lymphocyte proliferation was measured as an indicator of cell immunity and immune cell function. The results showed that the proliferation of lymphocytes from immunization with BP-IV and AIV vaccine was higher than in chickens that received AIV vaccine control (panel C in Fig. 3 ). These results suggest that the bursal-derived peptide BP-IV could induce Th1 and Th2 type cytokine immune responses.
Immunomodulatory characteristics of BP-IV on immunized mice
We next examined the biological activity of BP-IV on the mice prime-boost immunization regimen to confirm the results of the chicken model. Anti-AIV antibodies of the sera at two weeks after the first and second immunization from mice immunized with AIV vaccine and 1 mg/mL BP-IV were significantly increased (panel A in Fig. 4 ; p ＜ 0.05). The endogenous cytokine levels of IL-4 and IFN- in mice immunized with AIV vaccine were also measured. As shown in panel B of Fig. 3 , IL-4 and IFN- cytokines were significantly increased in mice immunized with AIV vaccine and 1 mg/mL BP-IV (panel B in Fig. 4 ; p ＜ 0.05).
The effects of BP-IV on the immunophenotyping of splenic T lymphocytes were also assessed. The results showed that the percentage of CD3+CD4+T cells (p ＜ 0.01) and CD3+CD8+ T cells (p ＜ 0.05) increased significantly in mice immunized with AIV vaccine and BP-IV (panel C in Fig. 4 ). Taken together, these results showed that BP-IV has strong immunomodulatory effects in the humoral and cellular response to AIV vaccine in a mouse model.
Discussion
There are many different types of short peptides with immunomodulatory activity that can be used in specific clinical applications. For example, primary/secondary immune deficiencies and autoimmune disorders have been treated with the immunomodulatory peptide Thymopentin [20] . Bursin is a candidate for the specific factor responsible for B-cell differentiation [11] . In this study, we found that BP-IV has immunomodulating activities and exhibits strong immunomodulatory function in antigen-specific humoral and cellular immune responses. Moreover, BP-IV can regulate B cell differentiation, which integrates an important linking between humoral and cell-mediated immunity, including B cell development. The immunological impact of BP-IV on cell-mediated immunity and B cell development has provided numerous insights into specific immunotherapeutic strategies for enhancing immune responses and protective immunity.
As a novel peptide from the avian immune system, this peptide led us to examine the effects of BP-IV on B cell differentiation. To the best of our knowledge, birds and mammals evolved from a common reptilian ancestor and have many common immunological systems. The mouse model has been extensively employed to detect the biological effects of BP-IV. Myeloid differentiation and B-cell-fate can be determined by PU.1 expression level [18, 22] . Additionally, low concentrations of PU.1 protein have been reported to induce a B-cell fate, while high concentrations blocked B-cell development [6] . Several PU.1 knockout/mutant mouse strains have been generated and shown various phenotypic changes. PU.1 knockout mice showed an obvious lack of T and B cells [15, 19] . These results indicate that BP-IV might modulate B/T cell-mediated immune responses, including antibody generation, cytokine production, and T cell maturation. Our previous study showed that BP5 can activate B cell proliferation directly and activate T cell proliferation indirectly, regulating both humoral immunity and cellular immunity [11] . BP11 also exerted immunomodulatory function on antigen-specific immune responses. However, BP11 could only increase IL-4 cytokine production [13] . When compared to BP5, BP11 and other adjuvants, such as oil and aluminum adjuvants, the biologically active peptide BP-IV acts as an adjuvant, activating humoral immunity and cellular immunity.
In summary, BP-IV was successfully isolated from the bursa of Fabricius through RP-HPLC and MALDI-TOF-MS methods and exhibited strong immunomodulatory function. Additionally, analysis of CFU pre-B formation showed that BP-IV could regulate B cell differentiation. These results suggest that the potential activity to regulate B cell differentiation indicates that BP-IV might act as an immunomodulatory factor, and therefore be useful as an agent for developing effective immunopharmacological strategies.
